Modulation of glucocorticoid metabolism by the GH-IGF-I axis

Endocrine Development

Volumn 20, Issue , 2010, Pages 181-186

  Neggers, Sebastian J C M M ^a   Van Der Lely, Aart J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; INSULIN; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ARTICLE; CORTICOSTEROID METABOLISM; GLUCOCORTICOID METABOLISM; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FUNCTION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; GLUCOCORTICOIDS; GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; METABOLIC DISEASES; METABOLIC NETWORKS AND PATHWAYS;

EID: 78751473069     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000321243     Document Type: Article

References (21)

1. Moller N, Jorgensen JO: Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009;30:152-177.
2. Quinn SM, Baur LA, Garnett SP, Cowell CT: Treatment of clinical insulin resistance in children: a systematic review. Obes Rev 2010;11:722-730.
3. Cooper MS, Stewart PM: 11β-Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamuspituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009;94: 4645-4654.
4. Ahmed A, Saksena S, Sherlock M, Olliff SP, Elias E, Stewart PM: Induction of hepatic 11β-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin Endocrinol (Oxf) 2008;68:898-903.
5. Moller N, Vendelbo MH, Kampmann U, Christensen B, Madsen M, Norrelund H, Jorgensen JO: Growth hormone and protein metabolism. Clin Nutr 2009; 28:597-603.
6. Salgin B, Marcovecchio ML, Humphreys SM, Hill N, Chassin LJ, Lunn DJ, Hovorka R, Dunger DB: Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects. Am J Physiol 2009;296:E454-E461.
7. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK: Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000;85:4712-4720.
8. Frystyk J, Delhanty PJ, Skjaerbaek C, Baxter RC: Changes in the circulating IGF system during shortterm fasting and refeeding in rats. Am J Physiol 1999;277:E245-E252.
9. Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM: Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 1999;84:4172-4177.
10. Li RS, Nakagawa Y, Liu YJ, Fujisawa Y, Sai S, Nakanishi T, Chapman KE, Seckl JR, Ohzeki T: Growth hormone inhibits the 11β-hydroxysteroid dehydrogenase type 1 gene promoter activity via insulin-like growth factor I in HepG2 cells. Horm Metab Res 2000;40:286-288.
11. Nakae J, Kido Y, Accili D: Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001;22:818-835.
12. Stewart PM, Toogood AA, Tomlinson JW: Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res 2001;56(suppl 1):1-6.
13. Tomlinson JW, Durrani OM, Bujalska IJ, Gathercole LL, Tomlins PJ, Reuser TT, Rose GE, Curnow SJ, Stewart PM, Walker EA, Rauz S: The role of 11β-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2010;95:398-406.
14. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM, Kumar S: 11β-Hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:4755-4761.
15. Liu YJ, Nakagawa Y, Ohzeki T: Gene expression of 11β-hydroxysteroid dehydrogenase type 1 and type in the kidneys of insulin-dependent diabetic rats. Hypertension 1998;31:885-889.
16. Shishko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC: Insulin-like growth factors and binding proteins in patients with recent-onset type(insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 1994;25:1-12.
17. Yuen KC, Dunger DB: Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Diabetes Obes Metab 2007;9:11-22.
18. Gathercole LL, Stewart PM: Targeting the prereceptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol 2010;122:21-27.
19. Mondok A, Varga I, Glaz E, Szucs N, Toth M, Patocs A, Beko G, Racz K: 11β-Hydroxysteroid dehydrogenase activity in acromegalic patients with normal or impaired carbohydrate metabolism. Steroids 2009; 74:725-729.
20. Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP: Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 2001;86:2989-2992.
21. Bidlingmaier M, Freda PU: Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm IGF Res 2010;20:19-25.